Department of Medicinal Biotechnology, Graduate School of Pharmaceutical Sciences, Tokushima University, Tokushima 770-8505, Japan.
Department of Medicinal Biotechnology, Faculty of Pharmacy, Tokushima University, Tokushima 770-8505, Japan.
ACS Appl Bio Mater. 2022 Jan 17;5(1):205-213. doi: 10.1021/acsabm.1c01043. Epub 2021 Dec 9.
Human neuraminidase 1 (NEU1) is a lysosomal glycosidase that cleaves the terminal sialic acids of sialylglycoconjugates. NEU1 is biosynthesized in the endoplasmic reticulum (ER) lumen as an -glycosylated protein. NEU1 also associates with cathepsin A (CTSA) in ER, migrates to lysosomes, and exerts catalytic activity. Extraordinary in cellulo crystallization of NEU1 protein in ER despite carrying three -glycans per molecule at N186, N343, and N352, respectively, were observed when the single human NEU1 gene was overexpressed in mammalian cells. In this study, we first purified the NEU1 from the isolated crystals produced by the HEK293 -KO cell transiently overexpressing the normal and found that the -glycans were high-mannose or complex types carrying terminal sialic acids. The result suggests that a part of NEU1 crystals were formed or transported to the Golgi apparatus. Second, we compared the effects of single amino acid substitution at the -sequons, including N186Q, N343Q, and N352Q, each one -glycan reduction from one NEU1 molecule. We demonstrated that N186Q mutant protein with low enzyme activity and formed a few amounts of smaller crystals. The N343Q mutant exhibited half of the normal intracellular activity, but the numbers and sizes of crystals were almost the same as those of normal NEU1. The N352Q mutant exhibited almost the same activity as the normal enzyme. The numbers of the N352Q crystals were smaller than those of normal NEU1. According to these findings, the N186Q NEU1 protein should have lower stability in ER due to abnormal folding. The second -glycan at the N343-sequon has little effect on self-aggregation of NEU1. The third -glycan at the N352-sequon contributes to the self-aggregation of NEU1. We also demonstrated that the three NEU1 mutants associate with the relatively excessive CTSA and migrate to lysosomes.
人神经氨酸酶 1(NEU1)是一种溶酶体糖苷酶,可裂解唾液酸糖缀合物的末端唾液酸。NEU1 在粗面内质网(ER)腔中作为 -糖基化蛋白生物合成。NEU1 还与 ER 中的组织蛋白酶 A(CTSA)结合,迁移到溶酶体,并发挥催化活性。尽管在单个 NEU1 基因在哺乳动物细胞中超表达时,每个分子在 N186、N343 和 N352 处分别携带三个 -聚糖,但在 ER 中观察到 NEU1 蛋白的非凡细胞内结晶。在这项研究中,我们首先从瞬时过表达正常人和发现的分离晶体中纯化 NEU1,发现 -聚糖是带有末端唾液酸的高甘露糖或复合类型。结果表明,一部分 NEU1 晶体是在形成或运输到高尔基体。其次,我们比较了 -序列单一位点氨基酸取代的影响,包括 N186Q、N343Q 和 N352Q,每个 NEU1 分子减少一个 -聚糖。我们证明了具有低酶活性和形成少量较小晶体的 N186Q 突变体蛋白。N343Q 突变体表现出正常细胞内活性的一半,但晶体的数量和大小几乎与正常 NEU1 相同。N352Q 突变体表现出与正常酶几乎相同的活性。N352Q 晶体的数量小于正常 NEU1 的晶体数量。根据这些发现,由于异常折叠,N186Q NEU1 蛋白在 ER 中的稳定性应该较低。N343-序列上的第二个 -聚糖对 NEU1 的自聚集几乎没有影响。N352-序列上的第三个 -聚糖有助于 NEU1 的自聚集。我们还证明,三种 NEU1 突变体与相对过量的 CTSA 结合并迁移到溶酶体。